Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393)

  • 18 Accesses

Abstract

Recombinant hirudins are currently under investigation for use in myocardial infarction and unstable angina. In this study the influence of piroxicam on the pharmacodynamics and pharmacokinetics of a recombinant hirudin preparation (CGP 39393) administered intravenously was determined. Twelve healthy, male volunteers received piroxicam 10 mg and matching placebo once daily for 12 days according to a double-blind, randomised cross-over design. On the 12th day, the dose of piroxicam was followed by a 6-hour infusion of hirudin 0.1 mg·kg−1·h−1. Plasma concentrations and urinary excretion of hirudin and repeated measurements of the activated partial thromboplastin time (APTT), bleeding time and platelet adhesion index were assessed up to 24 h after the start of the infusion. The maximum APTT was 83 s (placebo) and 84 s (piroxicam), 3 to 4 h after the start of the infusion, and was comparable on both study days. The AUD0–24 (APTT) came to 913 s·h·kg−1 under placebo and it was slightly increased to 1,017 s·h·kg−1 after piroxicam; the 95%-confidence interval according to MOSES ranged from 0.97 to 1.24, and the point estimator was 1.10. Bleeding time was significantly prolonged from 290 s under placebo to 345 s under piroxicam before the start of the infusion of hirudin. No further prolongation was found during or after the infusion. No change was observed in the platelet adhesion index. Responsiveness parameters according to a sigmoidal Emax-model were obtained from the hirudin-plasma concentration/effect (i.e. APTT-prolongation)-curves after placebo and piroxicam. Maximal APTT-prolongation (Emax; i.e. peak APTT minus the baseline value) was 53 s after placebo and 52 s after piroxicam. The EC50 was 34 nmol·l−1 after placebo and 40 nmol·h·l−1 after piroxicam. The AUC0 of hirudin was to 539 nmol·h·l−1·kg−1 under placebo and 557 nmol·h·l−1·kg−1 after piroxicam coadministration; the 95%- confidence interval according to MOSES ranged from 0.95 to 1.14, and the point estimator was 1.03. No period effect was detected. There were no significant differences between the other pharmacokinetic parameters except Vss, which was increased slightly from 0.23 l to 0.27 l under piroxicam. The results do not show a clinically relevant pharmacodynamic and/or pharmacokinetic interaction between hirudin and piroxicam.

This is a preview of subscription content, log in to check access.

References

  1. Bos AA van den, Deckers JW Heyndrickx GR, Laarman G-J, Suryapranata H, Zijlstra F, Close P, Rijnierse JJMM, Buller HR, Serruys PW (1993) Safety and efficacy of recombinant hirudin (hirudin) versus heparin in patients with stable angina undergoing coronary angioplasty. Circulation 88:2058–2066

  2. Breddin KH (1964) Zur Messung der Thrombozytenadhäsivität. Thromb Diath Haemorrh 12:269–280

  3. Brogden RN, Heel RC, Speight TM, Avery GS (1981) Piroxicam: a review of its pharmacological properties and therapeutic efficacy. Drugs 22:165–187

  4. Cannon CP, McCabe CH, Henry TD, Rogers WJ, Schweiger M, Gibson RS, Anderson JL, Williams DO, Braunwald E (1993) Hirudin reduces reocclusion compared to heparin following thrombolysis in acute myocardial infarction: results of the TIMI 5 trial (abstract). J Am Coll Cardiol 21 [Suppl 2]:136A

  5. Eriksson BI, Kälebo P, Ekman S, Lindbratt S, Kerry R, Close P (1994) Direct thrombin inhibition with rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement. Thromb Haemost 72:227–231

  6. Gold HK, Torres FW, Garabedian HD, Werne W, Jamng I, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D (1993) Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. J Am Coll Cardiol 21:1039–1047

  7. Heinzel G, Woloszczak R, Thomann P (1993) Pharmacokinetic and pharmacodynamic data analysis system. TOPFIT 2.0. Fischer, Stuttgart

  8. Kuhlmann J (1994) Drug interaction studies during drug development. Int J Clin Pharmacol Ther 32: 305–311

  9. Lang J, Price AB, Levi AJ, Burke M, Gumpel JM, Bjarnson I (1988) Diaphragm disease: pathology of disease of the small intestine induced by non-steroidal anti-inflammatory drugs. J Clin Pathol 41:516–526

  10. Märki WE, Wallis RB (1990) The anticoagulant and antithrombotic properties of hirudins. Thromb Haemost 64:344–348

  11. Marbet GA, Verstraete M, Kienast J, Graf P, Hoet B, Tsakiris DA, Silling-Engelhard D, Close P (1993) Clinical pharmacology of intravenously administered recombinant desulfatohirudin (hirudin) in healthy volunteers. J Cardiovasc Pharmacol 23:364–372

  12. Markwardt F (1991) Hirudin and derivates as anticoagulant agents. Thromb Haemost 66:141–152

  13. Mielke CH Jr, Kahn SB, Muschek LD, Tighe JJ, Ng KT, Minn FL (1980) Effects of zompirac on haemostasis in healthy volunteers and on platelet function in vitro. J Clin Pharmacol 20:409–417

  14. Müller H-J, Gundert-Remy U (1994) The regulatory view on drug-drug interactions. Int J Clin Pharmacol 32:269–273

  15. Neuhaus K-L, Niederer W, Wagner J, Mäurer W, Essen R von, Tebbe U, Leitner E-R von, Haerten K, Vogt A, Appel K-F, Mateblowski M, Zeymer U for the ALKK-Study Group (1993) HIT (Hirudin for the improvement of thrombolysis): results of a dose escalation study (abstract). Circulation 88 II [Suppl]: 1563

  16. Parent F, Bridey F, Dreyfus M, Musset D, Grimon G, Duroux P, Meyer D, Simonneau G (1993) Treatment of severe venous thrombo-embolism with intravenous hirudin (HBW 023): an open pilot study. Thromb Haemost 70:386–388

  17. Rane A, Oelz O, Frölich JC, Seyberth HW, Sweetman BJ, Watson JT, Wilkinson GR, Oates JA (1978) Relation between plasma concentration of indomethacin and its effect on prostaglandin synthesis and platelet function in man. Clin Pharmacol Ther 23: 658–668

  18. Sachs L (1992) Angewandte Statistik. Springer, Berlin Heidelberg New York

  19. Steinijans VW, Hartmann M, Huber R, Radtke HM (1991) Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Tox 29:323–328

  20. Talbot M, Ambler J, Butler KD (1989) Recombinant desulfatohirudin (hirudin), anticoagulant and antithrombotic properties in vivo. Thromb Haemostas 64: 344–348

  21. Tripodi A, Chantarangkul V, Arbini AA, Moia M, Mannucci PM (1993) Effects of hirudin on activated partial thromboplastin time determined with ten different reagents. Thromb Haemostas 70:286–288

  22. Weintraub M, Case K, Kroening B, Bosmann HB (1978) Effects of piroxicam on platelet aggregation. Clin Pharmacol Ther 23:134–135

  23. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, Cabot CF, Chesebro JH (1993) Recombinant hirudin in patients with chronic, stable coronary artery disease. Safety, half-life, and effect on coagulation parameters. Circulation 88:2015–2022

Download references

Author information

Correspondence to P. Thürmann.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Thürmann, P., Harder, S. & Kirchmaier, C.M. Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393). Eur J Clin Pharmacol 48, 241–246 (1995). https://doi.org/10.1007/BF00198305

Download citation

Key words

  • Recombinat hirudin
  • Piroxicam
  • activated partial thromboplastin time
  • pharmacokinetics
  • drug interaction